DI-030 Prescription profile of abiraterone in metastatic prostate carcinoma
DI-030 Prescription profile of abiraterone in metastatic prostate carcinoma
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Background In September 2011, the European Medicines Agency (EMA) approved the use of abiraterone for metastatic castration-resistant prostate cancer in men whose disease had progressed on docetaxel-based chemotherapy. In March 2012, abiraterone was included for this indication in our hospital’s formulary. Purpose To assess the prescription profile...
Alternative Titles
Full title
DI-030 Prescription profile of abiraterone in metastatic prostate carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2552746895
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2552746895
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2013-000436.201
